These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 14977208)

  • 1. Neuroprotection and dopamine agonists.
    Pirtosek Z; Flisar D
    Adv Exp Med Biol; 2004; 541():55-74. PubMed ID: 14977208
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroprotective role of dopamine agonists: evidence from animal models and clinical studies.
    Herrero MT; Pagonabarraga J; Linazasoro G
    Neurologist; 2011 Nov; 17(6 Suppl 1):S54-66. PubMed ID: 22045327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial treatment of Parkinson disease: levodopa or dopamine agonists.
    Weiner WJ
    Arch Neurol; 2004 Dec; 61(12):1966-9. PubMed ID: 15596623
    [No Abstract]   [Full Text] [Related]  

  • 4. D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease.
    Lewis MM; Huang X; Nichols DE; Mailman RB
    CNS Neurol Disord Drug Targets; 2006 Jun; 5(3):345-53. PubMed ID: 16787233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine agonists in the treatment of Parkinson's disease.
    Bonuccelli U; Pavese N
    Expert Rev Neurother; 2006 Jan; 6(1):81-9. PubMed ID: 16466315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targets for neuroprotection in Parkinson's disease.
    Yacoubian TA; Standaert DG
    Biochim Biophys Acta; 2009 Jul; 1792(7):676-87. PubMed ID: 18930814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical versus clinical neuroprotection.
    Grünblatt E; Schlösser R; Gerlach M; Riederer P
    Adv Neurol; 2003; 91():309-28. PubMed ID: 12442689
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease.
    Schapira AH
    Neurology; 2009 Feb; 72(7 Suppl):S44-50. PubMed ID: 19221314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotection in PD--a role for dopamine agonists?
    Schapira AH
    Neurology; 2003 Sep; 61(6 Suppl 3):S34-42. PubMed ID: 14504378
    [No Abstract]   [Full Text] [Related]  

  • 10. Medical management of Parkinson's disease.
    Clarke CE
    J Neurol Neurosurg Psychiatry; 2002 Mar; 72 Suppl 1(Suppl 1):I22-I27. PubMed ID: 11870200
    [No Abstract]   [Full Text] [Related]  

  • 11. Agonists vs levodopa in PD: the thrilla of whitha.
    Wooten GF
    Neurology; 2003 Feb; 60(3):360-2. PubMed ID: 12578913
    [No Abstract]   [Full Text] [Related]  

  • 12. [Parkinson's disease--new horizons].
    Bötzel K
    MMW Fortschr Med; 2004 Mar; 146(10):21-3. PubMed ID: 15347072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When and how should treatment be started in Parkinson disease?
    Lang AE
    Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
    Olanow CW
    Neurology; 2009 Feb; 72(7 Suppl):S59-64. PubMed ID: 19221316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions.
    Schapira AH; Olanow CW
    JAMA; 2004 Jan; 291(3):358-64. PubMed ID: 14734599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future therapies for Parkinson's disease.
    Hauser RA; Lyons KE
    Neurol Clin; 2004 Oct; 22(3 Suppl):S149-66. PubMed ID: 15501363
    [No Abstract]   [Full Text] [Related]  

  • 17. [The role of dopaminagonists in the treatment of Parkinson's disease].
    Ransmayr G
    Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
    Clarke CE
    Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Are there innovations in the treatment of Parkinson's disease?].
    Ludin HP
    Praxis (Bern 1994); 2004 Nov; 93(45):1865-8. PubMed ID: 15571301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease.
    Clarke CE
    Lancet Neurol; 2004 Aug; 3(8):466-74. PubMed ID: 15261607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.